Disease: Human Enterovirus Infections, HEV, (NCT04535648)

Disease info:

Enteroviruses, are picornaviruses (pico, or small, RNA viruses) and include coxsackieviruses A1 to A21, A24, and B1 to 6, echoviruses (enteric cytopathic human orphan viruses) 1 to 7, 9, 11 to 21, 24 to 27, and 29 to 33, enteroviruses 68 to 71, 73 to 91, and 100 to 101, and polioviruses types 1 to 3. 

Enteroviruses are shed in respiratory secretions and stool and sometimes are present in the blood and cerebrospinal fluid of infected patients. Infection is usually transmitted by direct contact with respiratory secretions or stool but can be transmitted by contaminated environmental sources (eg, water). Enteroviral diseases or epidemics in the US are more common in summer and fall.

Infection transmitted by a mother during delivery can cause severe disseminated neonatal infection, which may include hepatitis or hepatic necrosis, meningoencephalitis, myocarditis, or a combination of these, and can lead to sepsis or death. Intact humoral immunity and B-cell function are required for control of enteroviral disease. 

Diagnosis is made by clinical evaluation and sometimes culture or reverse transcriptase–polymerase chain reaction (RT-PCR). Laboratory diagnosis is usually unnecessary but can often be made by culturing the virus, detecting viral RNA using RT-PCR, less commonly, demonstrating seroconversion. 

Treatment of enteroviral disease is supportive. Patients with agammaglobulinemia are treated with IV immune globulins with variable success.

The oral antiviral drug pleconaril, which has shown activity against a number of picornaviruses, is being investigated for treatment of severe neonatal enteroviral disease.

Frequency:
Enteroviral infections account for at least one third of neonatal febrile admissions for suspected sepsis overall, and for between half and two thirds of admissions during peak enteroviral season.
Official title:
Rapid Identification and Clinical Transformation of Various Enterovirus Genotypes Based on CRISPR Technology
Partners:
Locations:

Shangai, China

Study start:
Oct. 12, 2020
Enrollment:
500 participants
Method:
CRISPR-enterovirus detection system
Condition:
Human Enterovirus Infections,, HEV

Status: Active recruiting

Description

To construct CRISPR-enterovirus detection system, we screened the targets, primers and CrRNA and evaluated the capability of this detecting system. Samples of feces, blood and cerebrospinal fluid (the remainder of routine testing samples) from 500 children with suspected or confirmed enterovirus infection were examined using the CRISPR technique. To evaluate the CRISPR-enterovirus detection system, real-time PCR and traditional PCR as comparison method was implemented. The method of real-time PCR and traditional PCR were used to detect enterovirus and analyze the genotypes of enterovirus, respectively. According to the results of CRISPR-enterovirus detection system and the comparison method, the positive coincidence rate, negative coincidence rate and consistency of the two methods were calculated. Furthermore, the sensitivity and specificity of the CRISPR-enterovirus detection system for detection of enterovirus were calculated.

Last updated: Jun. 6, 2021
close
Search CRISPR Medicine